Nama's AI scorecard currently rates Spyre Therapeutics Sell (3.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does SYRE report earnings?

Spyre Therapeutics's next scheduled report is on Feb 18, 2027. Analysts expect EPS of -$0.87.

What is the SYRE price target?

The median analyst price target from 15 analysts is $124.00, with a range of $110.00 – $135.00.

Is SYRE Shariah compliant?

Nama's AAOIFI-style screen reads Spyre Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Spyre Therapeutics (SYRE)

Healthcare · Biotechnology · NASDAQ

Spyre Therapeutics (SYRE) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $9.86B and a free-cash-flow yield of -2.1%. Nama's AI scorecard rates it Sell, 3.2 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 3.2/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Leading · +261.1% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-44.9%

How far the last close sits under the highest price of the past five years.

Market cap	$9.86B
Trailing P/E	—
Price / book	8.3
Price / sales	—
FCF yield	-2.1%
Dividend yield	—
Gross margin	0.0%
Operating margin	0.0%
Net margin	0.0%
Revenue growth (YoY)	—
Revenue growth (3-yr annual)	-100.0%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	3.1
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

SYRE earnings

Next report: Feb 18, 2027 (Q4 2026, EPS estimate -$0.87). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 3, 2026	-$0.94	-$0.84	-11.9%	$0
Q2 2026	Aug 4, 2026	-$0.36	-$0.75	+52.0%	$0
Q1 2026	May 5, 2026	-$0.74	-$0.65	-13.8%	$0
Q4 2025	Feb 19, 2026	-$0.74	-$0.80	+7.5%	$0

SYRE analyst price target

Median target $124.00 from 15 analysts, ranging $110.00 – $135.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live SYRE data on Nama Insights →

SYRE FAQ

Is SYRE a buy?: Nama's AI scorecard currently rates Spyre Therapeutics Sell (3.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does SYRE report earnings?: Spyre Therapeutics's next scheduled report is on Feb 18, 2027. Analysts expect EPS of -$0.87.
What is the SYRE price target?: The median analyst price target from 15 analysts is $124.00, with a range of $110.00 – $135.00.
Is SYRE Shariah compliant?: Nama's AAOIFI-style screen reads Spyre Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.